Joseph S. Zakrzewski - 22 Jun 2021 Form 4 Insider Report for Cyteir Therapeutics, Inc.

Role
Director
Signature
/s/ Andrew Gengos, Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
22 Jun 2021
Net transactions value
$0
Form type
4
Filing time
24 Jun 2021, 20:54:15 UTC
Previous filing
17 Jun 2021
Next filing
22 Nov 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CYT Common Stock Conversion of derivative security +58,671 58,671 22 Jun 2021 See Footnote F1, F2
holding CYT Common Stock 149,051 22 Jun 2021 See Footnote F3, F4
holding CYT Common Stock 77,267 22 Jun 2021 Direct F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CYT Series B Convertible Preferred Stock Conversion of derivative security -200,000 -100% 0 22 Jun 2021 Common Stock 58,671 See Footnote F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each share of Series B Convertible Preferred Stock converted into shares of Common Stock at a ratio of 3.4088:1 upon completion of the Issuer's initial public offering. The shares have no expiration date.
F2 Shares held by Z Investments, LLC, of which the Reporting Person is the Managing Director. The Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of his pecuniary interest therein.
F3 115,208 of the shares of common stock held directly and indirectly by the Reporting Person were acquired upon early exercise of an option and are subject to forfeiture until they vest.
F4 Shares held by Z3 Trust, of which the Reporting Person is a Trustee. The Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of his pecuniary interest therein.